1. Large retroperitoneal lymphadenopathy and increased risk of venous thromboembolism in patients receiving first‐line chemotherapy for metastatic germ cell tumors: A study by the global germ cell cancer group (G3)
- Author
-
Ben Tran, Jose M. Ruiz‐Morales, Enrique Gonzalez‐Billalabeitia, Anna Patrikidou, Eitan Amir, Christoph Seidel, Carsten Bokemeyer, Christian Fankhauser, Thomas Hermanns, Alexey Rumyantsev, Alexey Tryakin, Margarida Brito, Aude Fléchon, Edmond Michael Kwan, Tina Cheng, Daniel Castellano, Xavier Garcia del Muro, Anis A. Hamid, Margaret Ottaviano, Giovannella Palmieri, Robert Kitson, Alison Reid, Daniel Y. C. Heng, and Philippe L. Bedard
- Subjects
deep vein thrombosis ,germ cell tumor ,pulmonary embolism ,testicular cancer ,vascular access device ,venous thromboembolism ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Background Metastatic germ cell tumor (mGCT) patients receiving chemotherapy have increased risk of life‐threatening venous thromboembolism (VTE). Identifying VTE risk factors may guide thromboprophylaxis in this highly curable population. Methods Data were collected from mGCT patients receiving first‐line platinum‐based chemotherapy at 22 centers. Predefined variables included International Germ Cell Cancer Collaborative Group (IGCCCG) risk classification, long‐axis diameter of largest retroperitoneal lymph node (RPLN), Khorana score, and use of indwelling vascular access device (VAD). VTE occurring at baseline, during chemotherapy and within 90 days, was analyzed. Results Data from 1135 patients were collected. Median age was 31 years (range 10‐74). IGCCCG risk was 64% good, 20% intermediate, and 16% poor. VTE occurred in 150 (13%) patients. RPLN >3.5 cm demonstrated highest discriminatory accuracy for VTE (AUC 0.632, P
- Published
- 2020
- Full Text
- View/download PDF